Clarity with INHindsight: High-Dose Isoniazid for Drug-Resistant Tuberculosis with Mutations.
作者信息
Wasserman Sean, Furin Jennifer
机构信息
Department of Medicine.
Wellcome Centre for Infectious Diseases Research in AfricaUniversity of Cape TownCape Town, South Africaand.
出版信息
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1331-1333. doi: 10.1164/rccm.202002-0264ED.
Abstract
摘要
相似文献
1
Clarity with INHindsight: High-Dose Isoniazid for Drug-Resistant Tuberculosis with Mutations.事后之明带来的清晰认识：高剂量异烟肼治疗具有突变的耐多药结核病
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1331-1333. doi: 10.1164/rccm.202002-0264ED.
2
High Prevalence of inhA Promoter Mutations among Patients with Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa.南非夸祖鲁-纳塔尔省耐多药结核病患者中inhA启动子突变的高流行率
PLoS One. 2015 Sep 2;10(9):e0135003. doi: 10.1371/journal.pone.0135003. eCollection 2015.
3
Prevalence of isoniazid resistance-conferring mutations associated with multidrug-resistant tuberculosis in Free State Province, South Africa.南非自由州省与耐多药结核病相关的异烟肼耐药突变体的流行情况。
S Afr Med J. 2019 Aug 28;109(9):659-664. doi: 10.7196/SAMJ.2019.v109i9.13730.
4
Correlating genetic mutations with isoniazid phenotypic levels of resistance in Mycobacterium tuberculosis isolates from patients with drug-resistant tuberculosis in a high burden setting.在高负担环境下，将耐药结核病患者的结核分枝杆菌分离株中的基因突变与异烟肼表型耐药水平相关联。
Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2551-2561. doi: 10.1007/s10096-021-04316-0. Epub 2021 Jul 23.
5
6
Detection of mutations associated with isoniazid resistance in multidrug-resistant Mycobacterium tuberculosis clinical isolates.检测耐多药结核分枝杆菌临床分离株中与异烟肼耐药相关的突变。
J Antimicrob Chemother. 2014 Sep;69(9):2369-75. doi: 10.1093/jac/dku161. Epub 2014 May 22.
7
High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations.高水平耐异烟肼和乙硫异烟胺与利什曼家族的耐多药结核分枝杆菌中的 inhA 双重突变有关。
J Antimicrob Chemother. 2013 Aug;68(8):1728-32. doi: 10.1093/jac/dkt090. Epub 2013 Mar 28.
8
The mutations of katG and inhA genes of isoniazid-resistant Mycobacterium tuberculosis isolates in Taiwan.台湾地区异烟肼耐药结核分枝杆菌分离株 katG 和 inhA 基因突变。
J Microbiol Immunol Infect. 2015 Jun;48(3):249-55. doi: 10.1016/j.jmii.2013.08.018. Epub 2013 Nov 1.
9
Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis in Mongolia.蒙古结核分枝杆菌中与异烟肼耐药相关的基因突变
Antimicrob Agents Chemother. 2020 Jun 23;64(7). doi: 10.1128/AAC.00537-20.
10
[Cross-resistance between isoniazid and ethionamide and its strong association with mutation C-15T in Mycobacterium tuberculosis isolates from Peru].[秘鲁结核分枝杆菌分离株中异烟肼与乙硫异烟胺之间的交叉耐药性及其与C-15T突变的强关联]
Rev Argent Microbiol. 2020 Jan-Mar;52(1):36-42. doi: 10.1016/j.ram.2019.03.005. Epub 2019 Jun 27.
引用本文的文献
1
Precision Medicine Strategies to Improve Isoniazid Therapy in Patients with Tuberculosis.精准医学策略改善结核病患者的异烟肼治疗。
Eur J Drug Metab Pharmacokinet. 2024 Sep;49(5):541-557. doi: 10.1007/s13318-024-00910-7. Epub 2024 Aug 17.
2
The efficacy and safety of high-dose isoniazid-containing therapy for multidrug-resistant tuberculosis: a systematic review and meta-analysis.含高剂量异烟肼治疗耐多药结核病的疗效与安全性：一项系统评价与荟萃分析
Front Pharmacol. 2024 Jan 8;14:1331371. doi: 10.3389/fphar.2023.1331371. eCollection 2023.
3
Pharmacogenetics as part of recommended precision medicine for tuberculosis treatment in African populations: Could it be a reality?药物遗传学作为非洲人群结核病治疗推荐精准医学的一部分：这会成为现实吗？
Clin Transl Sci. 2023 Jul;16(7):1101-1112. doi: 10.1111/cts.13520. Epub 2023 Jun 8.
4
"Upcycling" known molecules and targets for drug-resistant TB.将已知的耐药结核病药物分子和靶点进行“升级利用”。
Front Cell Infect Microbiol. 2022 Oct 6;12:1029044. doi: 10.3389/fcimb.2022.1029044. eCollection 2022.
5
Investigating resistance in clinical Mycobacterium tuberculosis complex isolates with genomic and phenotypic antimicrobial susceptibility testing: a multicentre observational study.采用基因组学和表型药敏试验检测临床结核分枝杆菌复合群分离株的耐药性：一项多中心观察性研究。
Lancet Microbe. 2022 Sep;3(9):e672-e682. doi: 10.1016/S2666-5247(22)00116-1. Epub 2022 Jul 27.
本文引用的文献
1
Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data.结核患者异烟肼耐药的流行情况和基因谱：跨国分析的横断面数据。
PLoS Med. 2020 Jan 21;17(1):e1003008. doi: 10.1371/journal.pmed.1003008. eCollection 2020 Jan.
2
Early Bactericidal Activity of Different Isoniazid Doses for Drug-Resistant Tuberculosis (INHindsight): A Randomized, Open-Label Clinical Trial.不同异烟肼剂量对耐多药结核病的早期杀菌活性（事后回顾）：一项随机、开放标签的临床试验
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1416-1424. doi: 10.1164/rccm.201910-1960OC.
3
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.耐药结核病治疗。美国胸科学会/美国疾病控制与预防中心/欧洲呼吸学会/美国感染病学会临床实践指南。
Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142. doi: 10.1164/rccm.201909-1874ST.
4
Isoniazid Resistance in Is a Heterogeneous Phenotype Composed of Overlapping MIC Distributions with Different Underlying Resistance Mechanisms.异烟肼耐药是一种由不同潜在耐药机制的 MIC 分布重叠组成的异质表型。
Antimicrob Agents Chemother. 2019 Jun 24;63(7). doi: 10.1128/AAC.00092-19. Print 2019 Jul.
5
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.一项针对耐利福平结核病的较短疗程的试验。
N Engl J Med. 2019 Mar 28;380(13):1201-1213. doi: 10.1056/NEJMoa1811867. Epub 2019 Mar 13.
6
Improved Outcomes With High-dose Isoniazid in Multidrug-resistant Tuberculosis Treatment in Haiti.高剂量异烟肼在海地耐多药结核病治疗中的改善结局。
Clin Infect Dis. 2019 Aug 1;69(4):717-719. doi: 10.1093/cid/ciz039.
7
Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries.九个非洲国家采用短程耐多药结核病方案的治疗结果。
Int J Tuberc Lung Dis. 2018 Jan 1;22(1):17-25. doi: 10.5588/ijtld.17.0498. Epub 2017 Nov 17.
8
Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis.一线药物治疗耐异烟肼结核病：系统评价和荟萃分析。
Lancet Infect Dis. 2017 Feb;17(2):223-234. doi: 10.1016/S1473-3099(16)30407-8. Epub 2016 Nov 17.
9
Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Newly Diagnosed Pulmonary TB Patients in Tanzania.异烟肼、吡嗪酰胺和乙胺丁醇在坦桑尼亚新诊断肺结核患者中的药代动力学
PLoS One. 2015 Oct 26;10(10):e0141002. doi: 10.1371/journal.pone.0141002. eCollection 2015.
10
Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.结核病药物研发：基于机制范式的历史与演进
Cold Spring Harb Perspect Med. 2015 Apr 15;5(8):a021147. doi: 10.1101/cshperspect.a021147.
Zotero 插件